Won Suh Kim

Won Suh Kim leads end-to-end planning for DNA sequencers at Element Biosciences, managing the transition from R&D to commercial scale-up. His background includes reagent consumables planning at Becton Dickinson (BD) and navigating the “vein-to-vein” complexities of cell therapy at Kite Pharma (Gilead Sciences). Won Suh focuses on bridging the gap between volatile supply chains and patient-critical demand. He holds a degree in Cognitive Science from UC San Diego, with a focus on human-computer interaction. Outside of work, he is an avid rock climber.